Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial (RICH)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Oladipupo Olafiranye, MD MS
- Phone Number: (214) 857-2923
- Email: Oladipupo.Olafiranye@va.gov
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15240
- Recruiting
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
-
Contact:
- Ning Feng
- Phone Number: 412-360-6191
- Email: ning.feng@va.gov
-
-
Texas
-
Dallas, Texas, United States, 75216-7167
- Recruiting
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
-
Contact:
- Oladipupo Olafiranye, MD MS
- Phone Number: (214) 857-2923
- Email: Oladipupo.Olafiranye@va.gov
-
Principal Investigator:
- Oladipupo Olafiranye, MD MS
-
-
Virginia
-
Richmond, Virginia, United States, 23249-0001
- Recruiting
- Hunter Holmes McGuire VA Medical Center, Richmond, VA
-
Contact:
- Ion Jovin
- Phone Number: 804-675-5419
- Email: ion.jovin@va.gov
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years
- Diagnosis of heart failure with reduced LVEF <50%
- Pre-procedure intravenous normal saline fluid restriction status
- Society for Cardiovascular Angiography and Interventions (SCAI) AKI risk score (>1%)
- Referral for coronary angiogram and/or PCI
- Suspected stable coronary artery disease or acute coronary syndrome
Exclusion Criteria:
- Inability to give informed consent
- Unstable BP (SBP > 200 or <80 mmHg) at the time of enrolment
- Upper limb peripheral arterial disease
- Unavailability of at least one arm for RIPC/Sham-RIPC application
- Kidney transplant
- Renal disease requiring dialysis
- Prior exposure to contrast media within 72hrs preceding coronary angiography
- Pregnancy
- Prisoner
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Remote ischemic preconditioning
3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
|
3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
Other Names:
|
|
Sham Comparator: Sham remote ischemic preconditioning
3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
|
3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Contrast-associated acute kidney injury
Time Frame: 24 and 48 hours time points
|
The investigators define contrast-associated acute kidney injury as a relative increase in serum creatinine of 0.3mg/dl compared with initial creatinine at 48 hours time point after coronary angiography and/or PCI.
The will obtain levels of serum creatinine at baseline, then at 24 and 48 hours time points.
|
24 and 48 hours time points
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
6 minute walk distance
Time Frame: 1 month
|
At one month follow-up, 6 minute walk test will be used to determine total distance walked in 6 minutes.
|
1 month
|
|
Major adverse kidney events
Time Frame: 3 months
|
Persistent renal dysfunction, renal replacement therapy, and death will be assessed at 3 months (90 days) to determine major adverse kidney events (MAKE90).
|
3 months
|
|
Brain Natriuretic Peptide (BNP)
Time Frame: 24 and 48 hours time points
|
BNP is a hormone that is primarily secreted from the ventricular myocardium in response to hemodynamic stimuli such as ventricular volume expansion and pressure overload.
The investigators will obtain levels of serum BNP at baseline, then at 24 and 48 hours.
|
24 and 48 hours time points
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Oladipupo Olafiranye, MD MS, VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Heart Diseases
- Renal Insufficiency
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Myocardial Ischemia
- Heart Failure
- Acute Kidney Injury
- Coronary Artery Disease
- Acute Coronary Syndrome
Other Study ID Numbers
Other Study ID Numbers
- NEPH-019-20S
- 1I01CX002045-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.